Economy of catalyst synthesis—convenient access to libraries of Di- and tetranaphtho azepinium compounds

Article abstract of DOI:10.3390/molecules23040750

Efficient optimization procedures in chiral catalysis are usually linked to a straightforward strategy to access groups of structurally similar catalysts required for fine-tuning. The ease of building up such ligand libraries can be increased when the str

Full text of DOI:10.3390/molecules23040750

molecules
Article
Economy of Catalyst Synthesis—Convenient Access
to Libraries of Di- and Tetranaphtho
Azepinium Compounds
Sorachat Tharamak 1, Christian Knittl-Frank 2 ID , Auraya Manaprasertsak 1, Anchulee Pengsook 1,
Lydia Suchy 2, Philipp Schuller 2, Barbara Happl 3, Alexander Roller 3 and Michael Widhalm 4,
*
1
Department of Chemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand;
sorachat.th@ku.th (S.T.); auraya.ma@ku.th (A.M.); anchulee.peng@ku.th (A.P.)
Institute of Organic Chemistry, University of Vienna, Währinger Straße 38, Wien 1090, Austria;
2
christian.knittl-frank@univie.ac.at (C.K.-F.); a01205005@unet.univie.ac.at (L.S.);
philipp.daniel.schuller@gmail.com (P.S.)
Institute of Inorganic Chemistry, University of Vienna, Währinger Straße 42, Wien 1090, Austria;
3
barbara.happl@univie.ac.at (B.H.); alexander.roller@univie.ac.at (A.R.)
Institute of Chemical Catalysis, University of Vienna, Währinger Straße 38, Wien 1090, Austria
4
*
Correspondence: m.widhalm@univie.ac.at; Tel.: +43-01-4277-70305
Academic Editors: Laura Palombi and Antonio Massa
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Received: 22 February 2018; Accepted: 20 March 2018; Published: 24 March 2018
Abstract: Efficient optimization procedures in chiral catalysis are usually linked to a straightforward
strategy to access groups of structurally similar catalysts required for fine-tuning. The ease of
building up such ligand libraries can be increased when the structure-modifying step (introduction
of a substituent) is done at a later stage of the synthesis. This is demonstrated for the extended
family of di- and tetranaphtho azepinium compounds, widely used as chiral phase transfer
catalysts (PTC). Using 2,6-diiodo-4,5-dihydro-3H-dinaphtho[2,1-c:10,20-e]azepine and 4,8-diiodo-6,7-
dihydro-5H-dibenzo[c,e]azepine, respectively, as key intermediates, 18 spiro-azepinium compounds
0
0
were synthesized in a total yield of 25–42% over 6–7 steps from 1,1 -binaphthyl-2,2 -dicarboxylic acid
or diphenic acid, respectively. The replacement of iodo groups with aryl substituents was performed
as the last or the penultimate step of the synthesis.
Keywords: 1,10-binaphthyl; biphenyl; Suzuki-Miyaura coupling; phase transfer catalyst
1. Introduction
For the practical application of organocatalytic transformations, an economic access to libraries of
potentially useful catalysts is essential. As organocatalytic reactions are still optimized empirically, easy
access to stepwise structural modification of catalysts is essential for thorough and rapid screening.
Synthetic work will be minimized if the modifiers are introduced at the latest stage possible of a
synthetic sequence. This necessitates the proper choice of a reactive precursor which can be readily
transformed to the chiral catalysts under mild reaction conditions compatible with other functional
groups already present.
A class of versatile organocatalysts like
dinaphthoazepinium backbone [ ]. Such catalysts have been applied as highly efficient PTCs,
references [2–5] most prominently for the allylation and benzylation of N-protected glycine esters [6–10].
1–4 (Figure 1) is based on the C2-symmetric
1
Variations were particularly made by changing N-substituents, as well as 3,30-aryl groups, with
different degrees of bulkiness and additional electron donating or withdrawing substituents [11–14].
Molecules 2018, 23, 750; doi:10.3390/molecules23040750
www.mdpi.com/journal/molecules

Molecules 2018, 23, 750
2 of 18
Figure 1. Phase transfer catalysts with dinaphthoazepinium backbone.
Comparison of Synthetic Concepts
Several routes to azepinium-type PTCs have been developed, starting either from commercially
available enantiopure 2,20-dihydroxy-1,10-binaphthyl or from 1,10-binaphthalene-2,20-dicarboxylic
acid, to yield a broad range of 3,30-diaryl-substituted bisazepinium compounds (see Scheme 1
for a summary). The published syntheses from 2,20-dihydroxy-1,10-binaphthalene required in
total 13 to 17 steps [15] with the introduction of 3,30-aryl substituents in the third, fifth or tenth
step of the linear sequence (8 or 12 steps). This in turn means that for each individual catalyst
2–5 steps had to be performed afterwards to complete the synthesis. An alternative approach used
1,10-binapthalene-2,20-dicarboxylic acid as the key intermediate, [16] which was typically prepared in
4 to 6 steps from binaphthol or 2-methylnaphthalene (for details see Supplementary Materials) [17,18].
In the latter case, an optical resolution procedure had to be performed. The corresponding
2,20-diisopropylester was ortho-metallated and converted into 3,30-diaryl-2,20-carboxylates (via the
diboronic acid). Three more steps led to the desired spiro-ammonium catalysts. Some improvement
was made by using other ortho-directing ester groups [19] and ortho-metallation/arylation of free
carboxylic acid, [20] which shortened the synthesis in several cases.
Scheme 1. Published syntheses of N-spiro-azepinium bromides 2.
Retrosynthetic analysis revealed that the economy of accessing azepinium compounds could be
improved when structures C and D with X = I, Br were chosen as key intermediates (Scheme 2). This
would allow the introduction of variable N-substituents at a late stage, just before attaching aromatic
groups at C-3 and C-30. (path C-B-A). Alternatively, azepine D can be prepared from C, followed by
3,30-arylation or quaternation of the nitrogen atom (path D-B-A vs. D-B0-A). Since halide substituents
are present in C and D, this is compatible with carboxylate as an ortho-directing group (E).

Molecules 2018, 23, 750
3 of 18
Scheme 2. Retrosynthetic approach to biarylazepinium type libraries (X, Y = Br, I).
2. Results and Discussion
Based on these considerations, an alternative synthetic protocol for
1–4
is presented in Scheme 3.
Intermediate
the last step (see the Materials and Methods section), was cyclized to azepinium salts 5A
diiodoazepine . In a preliminary feasibility study, it turned out that was a versatile precursor,
forming smoothly with various secondary amines (dibutylamine, dimethylamine, pyrrolidine,
piperidine, etc.). The subsequent twofold Suzuki-Miyaura coupling of ammonium salts yielded
1Aa 1Cc in good yield (62–90%, not optimized). In contrast, applying the same conditions to 16
(Scheme 3) resulted in a complex mixture from which triarylated ring-opened products 17a and 17b
could be isolated. The solid state structure of 17b was determined (Figure 2). Instead, ligands of type
and were accessible through dinaphthoazepine (intermediate D, X = I in Figure 1, crystal structure of
7, which is available in four steps from
6
[21] using an improved procedure for
–
C
or
8
7
5
–
2
3
8
◦
8·HBr in Figure 3). High yields were obtained when the temperature was kept at 60 C, however, if the
temperature was raised to 80 ◦C, considerable amounts of a sparingly soluble “diamino trimer” 8X
were isolated. Suzuki coupling afforded 9a–c in good yield and cyclization with non-racemic 10 or 11
gave 2a and 3a in 76–92% yield. In the latter case, characterisation of products was hampered due
–c
–c
to extreme broadening of NMR signals. In several cases, high temperature NMR (378 K in DMSO-d6)
gave more informative spectra. Proposed structures have been confirmed by HRMS and by X-ray
structure analysis in one case (3a, Figure 4). Similarly, dinaphthodibenzoazepinium compounds 4a–c
were obtained from diphenic acid 12. During synthesis of 14, the formation of small amounts (8–13%)
of N-spiro-bisazepinium bromide 14X could not be completely suppressed, however, it was easily
removed by chromatography. It is worth noting that 3a–c and 4a–c have been alternatively synthesized
from diiodo precursors 18 and 19, respectively in fair to good yields. However, chromatographic
purification of the azepinium salts proved difficult and in several cases much product was nonisolable
(Scheme 4). The contrasting reactivity of 16 and its failure as a precursor for 2a–c remains unclear.
The crystal structure did not show significant distortions pointing to steric strain in the azepine ring
(Figure 5).
The economic benefits of the synthetic concept towards chiral ammonium salts are various.
Synthesis of key intermediates
7 and 8 from diacid 6, and 14 from 12 can be done on a multi-gram
scale in 4 or 5 steps without requirement for column chromatography. The cyclization of
aqueous ammonia obviates the previously applied two-step methodology where 3,3 -diaryl substituted
dibromides were cyclized with allylamine, benzylamine or hydroxylamine followed by removal of
7 with
0
the allyl, benzyl or hydroxy substituent [15,22–26]. Side reactions can be largely suppressed if the
temperature is kept low during the cyclization step. The introduction of aryl substituents is now
shifted to the last step (1Aa–1Cc) or the penultimate step (2a–c, 3a–c, 4a–c).

Molecules 2018, 23, 750
4 of 18
Scheme 3. Access to PTC 1–4 (counter anions omitted). Reagents and Conditions: a: ArB(OH)2, Na2CO3,
◦
◦
Pd(Ph3P)4, toluene, 80 C, 4–20 h. b: R2NH, K2CO3, CH3CN, 80 C, 22–24 h. c: ref. [21]. d: NH3
◦
◦
◦
(25%), CH3CN, 60 C, 24 h. e: K2CO3, CH3CN, 90 C, 24 h. f: (1) Li-TMP, Me3SiCl, THF,
−
78 C to r.t.
(2) BH3
·
THF, THF, reflux, 24 h. (3) ICl, DCM,
−
40 ◦C, 2 h. (4) HBr, HOAc, reflux, 2 h. g: NH3 (25%),
◦
CH3CN, 50 C, 48 h.
While 12 is commercially available at a reasonable price, the synthesis of racemic or non-racemic
6
will be often performed by researchers. The costs and ease of accessing this important key intermediate
will also influence the decision on the practical application of a class of catalysts. Several routes to
6
have been published through the last decades. Particularly, practical considerations comprising
complexity of optical resolution, purification of intermediates, price and availability of reagents,
the time needed for preparation, ease of purification and overall yield might help to choose a synthetic
path. An overview and evaluation of methods can be found in the Supplementary Material.

Molecules 2018, 23, 750
5 of 18
Scheme 4. Arylation of diiodo-N-spiro-bisazepinium bromides 16, 18 and 19 under Suzuki conditions
(counter anions omitted). Reagents and Conditions: a: K2CO3, CH3CN, 80 ◦C, 12 h. b: ArB(OH)2,
◦
Na2CO3, Pd(Ph3P)4, toluene, 80 C, 4–24 h.
Figure 2. X-ray structure of 17b.

Molecules 2018, 23, 750
6 of 18
Figure 3. X-ray structure of 8·HBr (counterion and solvent molecules ommitted).
Figure 4. X-ray structure of 3a (counterion and solvent molecules ommitted).
Summarizing, we presented a highly flexible route to binaphthyl based azepinium compounds
with the aim to facilitate access to libraries of organocatalysts. Reference [27] As key intermediates,
4,8-diiodo-6,7-dihydro-5H-dibenzo[c,e]azepine 14 was prepared from diphenic acid 12 (five
steps, 59% overall yield) and 2,6-diiodo-4,5-dihydro-3H-dinaphtho[2,1-c:10,20-e]azepine
8
from
(five steps, 42% overall yield). Two more steps (Suzuki-Miyaura
coupling with various arylboronic acids followed by spiro-cyclization) afforded C2-symmetrical
ammonium salts in good yield. A similar protocol led to various dinaphthoazepinium bromides
1Aa–1Cc accessible from 3,30-diiodo-2,20-bis(bromomethyl)-1,10-binaphthyl 7 in two steps.
0
0
1,1 -binaphthyl-2,2 -dicarboxylic acid
6
2–4

Molecules 2018, 23, 750
7 of 18
Figure 5. X-ray structure of 16 (counterion and solvent molecules ommitted).
3. Materials and Methods
3.1. General Considerations
Melting points: Kofler melting point apparatus (Reichert Thermovar, Reichert Technologies,
Depew, NY, USA), uncorrected. NMR: recorded at 400.27 MHz, 500.32 MHz, or 600.25 MHz (1H) and
100.66 MHz, 125.81 MHz, or 150.95 MHz (13C), on AV 400, AV 500, AV 600 (Bruker Biospin, Billerica,
MA, USA) respectively. Chemical shifts δ
are reported in ppm; for 1H rel. to (residuals non-deuterated)
solvent signals (chloroform-d: 7.26, DMSO-d6: 2.50 ppm), for 13C to CDCl3 at 77.00 ppm, or DMSO-d6
at 39.52 ppm, respectively. Coupling patterns are designated as s(inglet), d(oublet), t(riplet), q(uartet),
m(ultiplet), p(seudo), and br(oad). 13C{1H}-NMR spectra are recorded in a J-modulated mode; signals
are assigned as C, CH, CH2, and CH3. MS: ESI or EI (ESI-Qq ao TOF mass spectrometer, 70 eV (Bruker,
Bremen, Germany).
Heptane (PE), dichloromethane (DCM), and ethyl acetate (EtOAc) were distilled, absolute THF
from sodium benzophenone ketyl, DCM and acetonitrile from CaH2; BH3 THF was used as a 1.0 molar
·
solution in THF, n-BuLi as a 2.5 molar solution in hexanes. All the other chemicals were analytical
grade and used as obtained. Purification by chromatography (MPLC) was performed on a Isolera
One flash purification system (Biotage, Uppsala, Sweden) with self-packed SiO2-cartridges (40–63
and a solvent gradient. Reported procedures have been followed to obtain , [21 10, [28 30] and
11 31 32]. (Note: For the sake of convenience compounds 1Aa 1Cc as well as precursors 5A 5C have
µm)
7
]
–
[
,
–
–
been synthesized in racemic form.)
3.2. Synthesis
1Aa–1Cc (General Procedure A). To ammonium salt 5A–C (0.1 mmol) dissolved in toluene (3 mL) in
a Schlenk tube was added Na2CO3 (1 mL of a 2 M solution) and arylboronic acid (0.4 mmol, dissolved
in a minimum amount of EtOH). The mixture was degassed before adding Pd(PPh3)4 (20 mol%, 23 mg)
and stirred at 80 ◦C (bath) under Ar atmosphere. After 4–20 h (TLC) DCM (10 mL) and water (10 mL)
was added and the aqueous phase was extracted with DCM (10 mL). The combined organic phases
were washed with KOH (20% in water, 10 mL) and sat. KBr solution (2
evaporated. The residue was subjected to MPLC (aminopropyl-SiO2, MeOH(0
products 1Aa–1Cc as pale yellow solids.
×
5 mL) and the solvents were
→
8%)/DCM) to give
4,4-Dibutyl-2,6-diphenyl-4,5-dihydro-3H-dinaphtho[2,1-c:10,20-e]azepin-4-ium bromide (1Aa) [27]: Yield:
62%; m.p.: 182–184 ◦C. 1H-NMR (CDCl3)
: 8.09 (s, 2H); 8.06 (br.d, J = 8.3 Hz, 2H); 7.64 (ddd, J = 8.0,
δ

Molecules 2018, 23, 750
8 of 18
5.8, 2.2 Hz, 2H); 7.52–7.65 (br.m, ~8H); 7.46–7.52 (br.m, 2H); 7.35–7.41 (m, 4H); 5.11 (d, J = 14.0 Hz, 2H);
3.65 (br.dd, J = 14.0, 1.4 Hz, 2H); 3.17 (br.t, J = 13.1 Hz, 2H); 2.56 (br.td, J = 12.3, 4.7 Hz, 2H); 0.80–1.05
(m, 6H); 0.62 (t, J = 7.0 Hz, 6H); 0.12 (m, 2H) ppm. 13C-NMR (CDCl3)
δ: 140.17 (C); 138.69 (C); 138.41
(C); 133.95 (C); 131.11 (CH); 130.72 (C); 129.65 (2CH); 128.53 (CH); 128.32 (CH); 128.25 (CH); 127.61
(CH); 127.40 (CH); 123.92 (C); 57.50 (CH2); 57.21 (CH2); 24.14 (CH2); 19.53 (CH2); 13.30 (CH3) ppm.
HRMS (ESI) m/z: calcd. for C42H42N [M − Br]+: 560.3312, found: 560.3313.
4,4-Dibutyl-2,6-di(naphthalen-2-yl)-4,5-dihydro-3H-dinaphtho[2,1-c:10,20-e]azepin-4-ium bromide (1Ab):
Yield: 89%; m.p.: 255–260 ◦C. 1H-NMR (CDCl3)
δ
: 8.21 (br.s, 2H); 8.03 (br.d, J = 8.3 Hz, 2H); 7.67 (ddd,
J = 8.1, 5.2, 2.7 Hz, 2H); 7.50–7.61 (m, 4H); 7.37–7.48 (m, 4H); 5.10 (br.m, 2H); 3.75 (d, J = 13.6 Hz, 2H);
3.05 (br.t, J = 12.6 Hz, 2H); 2.61 (m, 2H); 0.4–0.9 (br.m, ~14H) ppm. In addition a broad band was
observed (7.6–8.2 ppm) corresponding to ~10H. 13C-NMR (CDCl3)
: 140.15 (C); 138.46 (C); 134.03 (C);
−
δ
132.62 (C); 131.43 (br.CH); 130.81 (C); 129.41 (br.CH); 128.57 (CH); 128.32 (CH); 127.71 (CH); 127.46 (CH);
127.18 (CH); 127.01 (CH); 124.15 (br.C); 57.50 (br.2CH2); 24.19 (CH2); 19.42 (CH2); ~12.5 (br.CH3) ppm
(4CH and 2C not observed). HRMS (ESI) m/z: calcd. for C50H46N [M
−
Br]+: 660.3625, found 660.3626.
2,6-Di([1,10-biphenyl]-4-yl)-4,4-dibutyl-4,5-dihydro-3H-dinaphtho[2,1-c:10,20-e]azepin-4-ium bromide (1Ac) [27]:
◦
1
Yield: 82%; m.p.: 184–189 C. H-NMR (CDCl3) δ: 8.13 (s, 2H); 8.05 (d, J = 8.3 Hz, 2H); 7.83 (br.d,
J = 7.6 Hz, 4H); 7.61–7.73 (m, 10H); 7.42–7.49 (m, 4H); 7.34–7.42 (m, 6H); 5.19 (br.d, J = 13.3 Hz, 2H);
3.70 (br.d, J = 13.4 Hz, 2H); 3.20 (br.m, 2H); 2.61 (br.m, 2H); 0.8–1.2 (br.m, 6H); 0.55 (t, J = 6.6 Hz, 6H);
0.29 (br.m, 2H) ppm. 13C-NMR (CDCl3)
δ: 141.08 (C); 139.73 (C); 139.68 (C); 138.44 (C); 137.45 (C);
133.94 (C); 131.10 (CH); 130.68 (C); 128.91 (CH); 128.51 (CH); 128.28 (CH); 128.16 (CH); 127.78 (CH);
127.62 (CH); 127.43 (CH); 127.07 (CH); 123.84 (C); 57.41 (CH2); 57.10 (CH2); 24.36 (CH2); 19.60 (CH2);
13.39 (CH3) ppm. HRMS (ESI) m/z: calcd. for C54H50N [M − Br]+: 712.3938, found 712.3936.
2,6-Diphenyl-3,5-dihydrospiro[dinaphtho[2,1-c:10,20-e]azepine-4,10-piperidin]-4-ium bromide (1Ba): Yield:
88%; m.p.: 246–250 ◦C. 1H-NMR (CDCl3)
δ: 8.06 (s, 2H); 8.02 (d, J = 8.5 Hz, 2H); 7.63 (ddd, J = 8.1, 6.5,
1.4 Hz, 2H); 7.56 (m, 2H); 7.55 (br.d, J = 7.0 Hz, 2H); 7.44–7.51 (m, 8H); 7.39 (ddd, J = 8.6, 6.5, 1.3 Hz,
2H); 5.06 (d, J = 13.3 Hz); 3.61 (d, J = 13.3 Hz, 2H); 3.41 (m, 2H); 2.72 (m, 2H); 1.34 (br.m, 4H); 0.73
(br.m, 2H) ppm. 13C-NMR (CDCl3)
δ: 140.20 (C); 138.73 (C); 138.11 (C); 133.90 (C); 130.88 (CH); 130.61
(C); 130.15 (CH); 129.51 (CH); 128.56 (CH); 128.41 (CH); 128.22 (CH); 127.51 (CH); 127.38 (CH); 123.94
(C); 59.12 (CH2); 57.85 (CH2); 20.27 (CH2); 19.76 (CH2) ppm. HRMS (ESI) m/z: calcd. for C39H34N
[M − Br]+: 516.2686, found: 516.2699.
0
0
0
2,6-Di(naphthalen-2-yl)-3,5-dihydrospiro[dinaphtho[2,1-c:1 ,2 -e]azepine-4,1 -piperidin]-4-ium bromide (1Bb):
1
Yield: 90%; m.p.: 250–256 ◦C (dec.). H-NMR (CDCl3)
δ
: 8.16 (s, 2H); 7.86–8.14 (br.m, 10H); 7.36–7.75
(br.m, 12H); 5.16 (d, J = 13.1 Hz, 2H); 3.78 (d, J = 13.1 Hz, 2H); 3.39 (m, 2H); 2.69 (m, 2H); 1.19 (m,
2H); 1.04 (m, 2H); 0.57 (m, 2H) ppm. 13C-NMR (CDCl3)
: 140.18 (C); 138.24 (C); 136.20 (br.C); 134.00
δ
(C); 133.42 (br.C); 132.61 (C); 131.34 (CH); 130.73 (C); 129.38 (br.CH); 129.34 (CH); 128.63 (CH); 128.37
(br.CH); 128.31 (CH); 127.87 (CH); 127.67 (CH); 127.62 (CH); 127.47 (CH); 127.10 (CH); 126.95 (CH);
124.14 (C); 59.40 (CH2); 58.37 (br.CH2); 20.21 (CH2); 19.74 (CH2) ppm. HRMS (ESI) m/z: calcd. for
C47H38N [M − Br]+: 616.2999, found: 616.2994.
2,6-Di([1,10-biphenyl]-4-yl)-3,5-dihydrospiro[dinaphtho[2,1-c:10,20-e]azepine-4,10-piperidin]-4-ium bromide
(
1Bc): Yield: 70%; m.p.: 230–240 ◦C (slow dec. > 210 ◦C). 1H-NMR (CDCl3)
δ: 8.12 (s, 2H); 8.05 (d,
J = 8.2 Hz, 2H); 7.82 (d, J = 8.5 Hz, 2H); 7.82 (br.d, J = 6.5 Hz, 2H); 7.68–7.71 (m, 4H); 7.66 (ddd, J = 8.1,
6.6, 1.3 Hz, 2H); 7.59 (d, J = 8.2 Hz, 2H); 7.59 (m, 2H); 7.44–7.50 (m, 6H); 7.42 (ddd, J = 8.6, 6.7, 1.3 Hz,
2H); 7.37 (ddt, J = 7.8, 7.0, 1.3 Hz, 2H); 5.17 (d, J = 13.5 Hz, 2H); 3.69 (d, J = 13.4 Hz, 2H); 3.49 (m, 2H);
2.83 (m, 2H); 1.42 (m, 2H); 1.34 (m, 2H); 0.84 (m, 2H) ppm. 13C-NMR (CDCl3)
δ: 141.21 (C); 139.92 (C);
138.25 (C); 137.61 (C); 133.99 (C); 130.95 (CH); 130.70 (C); 130.66 (CH); 128.91 (CH); 128.62 (CH); 129.29
(CH); 128.15 (CH); 127.78 (CH); 127.59 (CH); 127.45 (CH); 127.22 (CH); 124.08 (C); 59.25 (CH2); 58.00
(br.CH2); 20.33 (CH2); 19.85 (CH2) ppm. HRMS (ESI) m/z: calcd. for C51H42N [M
found 668.3307.
−
Br]+: 668.3312,

Molecules 2018, 23, 750
9 of 18
2,6-Diphenyl-3,5-dihydrospiro[dinaphtho[2,1-c:10,20-e]azepine-4,10-pyrrolidin]-4-ium bromide (1Ca): Yield:
74%; m.p.: 224–228 ◦C. 1H-NMR (CDCl3)
: 8.08 (s, 2H); 8.04 (d, J = 8.2 Hz, 2H); 7.65 (ddd, J = 8.1, 6.7,
δ
1.4 Hz, 2H); 7.56 (m, 2H); 7.54 (br.d, J = 6.8 Hz, 2H); 7.44–7.50 (m, 8H); 7.41 (ddd, J = 8.5, 6.6, 1.2 Hz,
2H); 4.85 (d, J = 13.5 Hz, 2H); 3.81 (d, J = 13.5 Hz, 2H); 3.46 (m, 2H); 2.96 (m, 2H); 1.81 (m, 2H); 1.24 (m,
2H) ppm. 13C-NMR (CDCl3)
δ
: 139.67 (C); 138.61 (C); 137.75 (C); 133.90 (C); 130.87 (CH); 130.68 (C);
130.10 (CH); 129.31 (CH); 128.57 (CH); 128.37 (CH); 128.13 (CH); 127.47 (CH); 127.33 (CH); 124.83 (C);
61.84 (CH2); 57.30 (CH2); 20.51 (CH2) ppm. HRMS (ESI) m/z: calcd. for C38H32N [M
found: 502.2543.
−
Br]+: 502.2529,
0
0
0
2,6-Di(naphthalen-2-yl)-3,5-dihydrospiro[dinaphtho[2,1-c:1 ,2 -e]azepine-4,1 -pyrrolidin]-4-ium bromide (1Cb):
Yield: 81%; m.p.: 275–280 ◦C (dec.). H-NMR (CDCl3)
δ: 8.17 (s, 2H); 8.07 (d, J = 8.4 Hz, 2H); 8.02 (d,
1
J = 8.8 Hz, 2H); 8.01 (s, 2H); 7.96 (m, 2H); 7.90 (m, 2H); 7.67 (ddd, J = 8.1, 6.7, 1.2 Hz, 2H); 7.60 (br.d,
J = 6.4 Hz, 2H); 7.51–7.57 (m, 6H); 7.45 (ddd, J = 8.4, 6.7, 1.2 Hz, 2H); 4.96 (d, J = 13.5 Hz, 2H); 3.95
(d, J = 13.4 Hz, 2H); 3.47 (m, 2H); 2.92 (m, 2H); 1.61 (m, 2H); 0.97 (m, 2H) ppm. 13C-NMR (CDCl3)
δ:
139.68 (C); 137.93 (C); 136.07 (br.C); 134.03 (C); 133.26 (br.C); 132.61 (C); 131.33 (CH); 130.81 (C); 129.34
(CH); 129.24 (CH); 128.68 (CH); 128.32 (CH); 128.25 (CH); 127.87 (CH); 127.64 (CH); 127.59 (CH); 127.47
(CH); 127.14 (CH); 126.98 (CH); 125.05 (C); 61.93 (CH2); 57.83 (CH2); 20.56 (CH2) ppm. HRMS (ESI)
m/z: calcd. for C46H36N [M − Br]+: 602.2842, found 602.2835.
2,6-Di([1,10-biphenyl]-4-yl)-3,5-dihydrospiro[dinaphtho[2,1-c:10,20-e]azepine-4,10-pyrrolidin]-4-ium bromide
(
1Cc): Yield: 89%; glassy material. 1H-NMR (600 MHz, CDCl3)
δ: 8.13 (s, 2H); 8.06 (d, J = 8.3 Hz,
2H); 7.80 (d, J = 8.2 Hz, 4H); 7.68 (br.d, J = 7.3 Hz, 4H); 7.66 (m, 2H); 7.57 (br.d, J = 7.9 Hz, 4H); 7.50
(d, J = 8.4 Hz, 2H); 7.44–7.47 (m, 4H); 7.43 (m, 2H); 7.37 (m, 2H); 4.96 (d, J = 13.5 Hz, 2H); 3.87 (d,
J = 13.5 Hz, 2H); 3.57 (m, 2H); 3.00 (m, 2H); 1.84 (m, 2H); 1.27 (m, 2H) ppm. 13C-NMR (151 MHz,
CDCl3) δ: 141.14 (C); 139.83 (C); 139.28 (C); 137.86 (C); 137.39 (C); 133.97 (C); 130.97 (CH); 130.69 (C);
130.62 (CH); 128.88 (CH); 128.64 (CH); 128.24 (CH); 128.01 (CH); 127.76 (CH); 127.54 (CH); 127.45
(CH); 127.19 (CH); 124.84 (C); 61.97 (CH2); 57.48 (CH2); 20.60 (CH2) ppm. HRMS (ESI) m/z: calcd. for
C50H40N [M − Br]+: 654.3155, found: 654.3134.
Spiro cyclization of (S)-9a–c –c,
with (S)-2,20-bisbromomethyl-1,10-binaphthyl 10 yielding (S,S)-2a
respectively. (General Procedure B): A Schlenk tube, equipped with magnetic stirring bar and glass
stopper, was charged with a solution of substrate (0.3 mmol) in MeCN (6 mL) and K2CO3 (83 mg,
2 eq) followed by (S)-2,20-bis(bromomethyl)-1,10-binaphthyl 10 (132 mg, 0.3 mmol) and the mixture
was degassed. The reaction was left stirring at 85–90 ◦C (bath) for 24 h. After cooling to r.t., DCM (30
mL) and H2O (30 mL) were added and the phases were separated. The aqueous one was extracted
with DCM (3
×
15 mL) and the combined organic extracts were evaporated under reduced pressure.
The crude material was purified by MPLC using a solvent gradient (MeOH(0→8%)/DCM).
(S,S)-2,6-Diphenyl-3,30,5,50-tetrahydro-4,40-spirobi[dinaphtho[2,1-c:10,20-e]azepin]-4-ium bromide (2a) [
8]:
1
Yield: 76%. H-NMR (CDCl3)
δ: 8.33 (s, 2H); 8.10 (br.d, J = 8.2 Hz, 2H); 7.83 (d, J = 8.1 Hz, 2H); 7.74
(m, 2H); 7.62 (ddd, J = 7.9, 6.5, 1.1 Hz, 2H); 7.48 (ddd, J = 7.9, 6.6, 1.1 Hz, 2H); 7.32 (ddd, J = 8.3, 6.8,
1.1 Hz, 2H); 7.32 (d, J = 8.5 Hz, 2H); 7.18 (ddd, J = 8.1, 6.8, 1.2 Hz, 2H); 7.12 (d, J = 8.6 Hz, 2H); 7.09
(d, J = 8.4 Hz, 2H); 6.32 (d, J = 8.4 Hz, 2H); 5.00 (d, J = 13.8 Hz, 2H); 4.38 (d, J = 13.7 Hz, 2H); 4.21
(d, J = 13.4 Hz, 2H); 3.69 (d, J = 13.3 Hz) ppm. In addition a broad band was observed (7.4–8.2 ppm)
corresponding to ~8H. 13C-NMR (CDCl3)
δ: 139.27 (C); 139.13 (C); 136.15 (C); 133.95 (C); 133.85 (C);
132.69 (CH); 131.02 (C); 130.96 (C); 130.89 (br. CH); 130.15 (br. CH); 129.04 (CH); 128.74 (CH); 128.52
(CH); 128.33 (CH); 128.18 (CH); 127.51 (2CH); 127.42 (CH); 127.34 (CH); 126.87 (CH); 126.70 (CH);
124.81 (C); 122.36 (C); 62.33 (CH2); 57.41 (CH2) ppm (1C not observed). HRMS (ESI) calcd. for C56H40N
[M − Br]+: 726.3161, found: 726.3171.
(S,S)-2,6-Di(naphthalen-2-yl)-3,30,5,50-◦tetrahydro-4,40-spirobi[dinaphtho[2,1-c:10,20-e]azepin]-4-ium bromide
]: Yield: 88%; m.p.: 255–258 C (dec.); [α]2D0 = +55 (c: 0.70, DCM). H-NMR (CDCl3)
δ: 8.47
1
(2b) [
8
(s, 2H); 8.15 (d, J = 8.1 Hz, 2H); 8.13 (br.m, 2H); 7.77 (br.m, 2H); 7.65 (ddd, J = 8.1, 6.8, 1.1 Hz, 2H);

Molecules 2018, 23, 750
10 of 18
7.30–7.42 (m, 6H); 7.19 (br.d, J = 8.7 Hz, 2H); 7.07 (ddd, J = 8.3, 6.7, 1.4 Hz, 2H); 6.94 (d, J = 8.7 Hz, 2H);
6.06 (br.m, 4H); 5.06 (br.m, 2H); 4.49 (d, J = 13.8 Hz, 2H); 4.20 (d, J = 13.2 Hz, 2H); 3.65 (d, J = 13.2 Hz,
2H) ppm. In addition a broad band was observed (7.5–9.1 ppm); integration corresponding to ~10H.
13C-NMR (CDCl3)
δ: 139.43 (C); 139.28 (C); 135.92 (C); 134.08 (C); 133.68 (C); 133.19 (C); 132.79 (br.CH);
131.27 (C); 130.75 (C); 129.97 (br.CH); 128.86 (br.CH); 128.57 (2CH); 128.40 (CH); 128.31 (br.CH); 127.95
(CH); 127.75 (br.CH); 127.59 (CH); 127.56 (CH); 127.30 (3CH); 127.19 (CH); 126.78 (br.CH); 126.56 (CH);
124.78 (C); 122.84 (C); 62.40 (CH2); 57.61 (br.CH2) ppm (1CH and 2C not observed). HRMS (ESI) calcd.
for C64H44N [M − Br]+: 826.3474, found: 826.3471.
(S,S)-2,6-Di([1,10-biphenyl]-4-yl)-3,30,5,50-tetrahydro-4,40-spirobi[dinaph-tho[2,1-c:10,20-e]azepin]-4-ium
bromide (2c): Yield: 81%; m.p.: 252–255 C (dec.); [α]2D0 = +140 (c: 0.81, DCM). 1H-NMR (CDCl3)
δ: 8.40
◦
(s, 2H); 8.12 (d, J = 7.9 Hz, 2H); 7.84 (m, 4H); 7.57–7.67 (m, 8H); 7.53 (m, 2H); 7.43 (ddd, J = 8.1, 6.7,
1.1 Hz, 2H); 7.32 (ddd, J = 8.2, 6.8, 1.1 Hz, 2H); 7.13–7.20 (m, 6H); 7.08 (d, J = 8.4 Hz, 2H); 6.41 (d,
J = 8.4 Hz, 2H); 5.08 (d, J = 13.8 Hz, 2H); 4.47 (d, J = 13.8 Hz, 2H); 4.27 (d, J = 13.4 Hz, 2H); 3.76 (d,
J = 13.4 Hz, 2H) ppm; in addition a broad band was observed (7.4–8.5 ppm); integration corresponding
to ~8H. 13C-NMR (CDCl3)
δ: 141.76 (C); 140.18 (C); 139.40 (C); 138.77 (C); 138.18 (C); 136.24 (C); 134.05
(C); 133.84 (C); 132.42 (CH); 131.48 (br. CH); 131.22 (C); 131.03 (C); 129.27 (CH); 128.82 (CH); 128.77
(CH); 128.58 (CH); 128.34 (CH); 128.11 (CH); 128.00 (CH); 127.54 (2CH); 127.41 (CH); 127.32 (CH);
126.83 (CH); 126.71 (CH); 125.05 (C); 122.67 (C); 62.51 (CH2); 57.43 (CH2) ppm (1CH not observed).
HRMS (ESI) calcd. for C68H48N [M − Br]+: 878.3781, found: 878.3781.
0 0
–c with 2,2 -bisbromomethyl-1,1 -biphenyl 10 yielding (S)-3a–c; a similar
Spiro cyclization of (S)-9a
procedure as for the synthesis of (S,S)-2a–c was applied.
(S)-20,60-Diphenyl-30,5,50,7-tetrahydrospiro[dibenzo[c,e]azepine-6,40-dinaphtho[2,1-c:10,20-e]azepin]-6-ium
bromide (3a): Yield: 89%; m.p.: 275–286 C (dec.); [α]2D0 = +12 (c: 0.51, DCM). H-NMR (500 MHz,
DMSO-d6, 378 K) : 8.28 (s, 2H); 8.25 (d, J = 8.1 Hz, 2H); 7.72 (br.ddd, J = 8.0, 6.7, 1.0 Hz, 2H); 7.1–7.6
(br.m, 22H); 4.66 (br.d, J = 13.2 Hz, 2H); 4.52 (d, J = 13.3 Hz, 2H); 4.16 (br.s, 2H); 2.87 (br.s, 2H) ppm.
13C-NMR (125.8 MHz, DMSO-d6, 378 K)
: 139.67 (C); 138.96 (C); 138.41 (C); 137.58 (C); 133.32 (C);
◦
1
δ
δ
130.44 (CH); 130.31 (C); 130.20 (CH); 129.57 (CH); 128.25 (CH); 128.08 (CH); 127.83 (CH); 127.49 (CH);
127.39 (CH); 127.31 (CH); 126.61 (CH); 126.57 (CH); 126.27 (C); 123.85 (br.C); 61.30 (CH2); 57.74 (CH2)
ppm. HRMS (ESI) calcd. for C48H36N [M − Br]+: 626.2842, found: 626.2839.
0
0
0
0
0
0
0
(S)-2 ,6 -Di(naphthalen-2-yl)-3 ,5,5 ,7-tetrahydrospiro[dibenzo[c,e]azepine-6,4 -dinaphtho[2,1-c:1 ,2 -e]-azepin]-
6-ium bromide (3b): Yield: 92%; m.p.: 264–267 C (dec.); [α]D20
=
−
21 (c: 0.35, DCM). 1H-NMR (500 MHz,
◦
DMSO-d6, 378 K) δ: 8.46 (s, 2H); 8.30 (d, J = 8.3 Hz, 2H); 8.18 (br.s, 2H); 8.00 (br.d, J = 8.2 Hz, 2H); 7.96
(br.d, J = 7.5 Hz, 2H); 7.92 (br.d, J = 7.3 Hz, 2H); 7.75 (ddd, J = 8.0, 7.0, 1.0 Hz, 2H); 7.73 (br.s, 2H); 7.58
(m, 4H); 7.51 (ddd, J = 8.2, 7.0, 1.1 Hz, 2H); 7.36 (br.d, J = 8.3 Hz, 2H); 7.23 (m, 4H); 6.76 (br.s, 2H);
6.57 (br.s, 2H); 4.85 (d, J = 13.9 Hz, 2H); 4.53 (d, J = 13.8 Hz, 2H); 3.97 (br.s, 2H); 3.13 (br.s, 2H) ppm.
13C-NMR (125.8 MHz, DMSO-d6, 378 K)
δ: 139.48 (C); 138.86 (C); 137.88 (br.C); 135.79 (C); 133.34 (C);
132.46 (br.C); 131.82 (C); 130.81 (CH); 130.37 (C); 130.14 (CH); 128.92 (CH); 128.24 (CH); 127.99 (CH);
127.50 (CH); 127.42 (CH); 127.35 (CH); 126.96 (CH); 126.74 (CH); 126.59 (CH); 126.24 (2CH); 125.98
(C); 123.70 (br.C); 61.10 (CH2); 57.56 (CH2) ppm (3CH not observed). HRMS (ESI) calcd. for C56H40N
[M − Br]+: 726.3155, found: 726.3145.
(S)-20,60-Di([1,10-biphenyl]-4-yl)-30,5,50,7-tetrahydrospiro[dibenzo[c,e]aze-pine-6,40-dinaphtho[2,1-c:10,20-e]
azepin]-6-ium bromide (3c): Yield: 84%; glassy material. [α]2D0 = +9 (c: 0.61, DCM). 1H-NMR (500 MHz,
DMSO-d6, 378 K)
(br.s, 4H); 4.79 (br.d, J = 13.0 Hz, 2H); 4.51 (d, J = 13.8 Hz, 2H); 4.10 (br.s, 2H); 3.08 (br.s, 2H) ppm.
13C-NMR (125.8 MHz, DMSO-d6, 378 K)
: 139.75 (C); 139.73 (C); 138.89 (C); 138.53 (C); 137.72 (C);
δ: 8.37 (s, 2H); 8.28 (d, J = 8.2 Hz, 2H); 7.55–7.80 (m, 14H); 7.31–7.54 (m, 14H); 7.17
δ
137.38 (C); 133.33 (C); 130.34 (C); 130.32 (CH); 130.27 (CH); 128.39 (CH); 128.25 (CH); 127.59 (br.CH);
127.51 (CH); 127.36 (CH); 127.17 (CH); 126.67 (CH); 126.57 (CH); 126.48 (CH); 126.29 (C); 126.11 (2CH);

Molecules 2018, 23, 750
11 of 18
123.79 (br.C); 61.21 (CH2); 57.49 (CH2) ppm (1CH not observed). HRMS (ESI) calcd for C60H44N
[M − Br]+: 778.3468, found: 778.3441.
(S)-4,8-Diphenyl-30,5,50,7-tetrahydrospiro[dibenzo[c,e]azepine-6,40-dinaphtho[2,1-c:10,20-e]azepin]-6-ium bromide
◦
(
4a) [14]: Yield: 82%; m.p.: 225–228 C; [α]2D0 = +225 (c: 0.49, DCM). 1H-NMR (CDCl3)
δ
: 6.66–8.10
(several broad m, ~24H), 7.92 (br.d, J = 8.3 Hz, ~2H); 7.18 (br.m, J = 8.8 Hz, ~2H); 4.60–4.75 (m, 4H); 4.43
(d, J = 13.3 Hz, 2H); 2.46–3.10 (br.m, 2H) ppm. 13C-NMR (CDCl3)
: 143.52 (C); 142.57 (br.C); 138.92 (C);
δ
136.27 (C); 134.00 (C); 130.95 (CH); 130.65 (C); 129.60 (br.CH); 129.53 (CH); 129.11 (CH); 128.33 (CH),
127.57 (br.CH); 127.21 (CH); 127.11 (2CH); 126.74 (CH); 126.09 (br.C); 124.16 (br.C); 63.17 (CH2); 57.86
(CH2) ppm; (2CH not observed). HRMS (ESI) calcd. for C48H36N [M
−
Br]+: 626.2842, found: 626.2828.
0
0
0
0
0
(S)-4,8-Di(naphthalen-2-yl)-3 ,5,5 ,7-tetrahydrospiro[dibenzo[c,e]azepine-6,4 -dinaphtho[2,1-c:1 ,2 -e]azepin]-6-
ium bromide (4b) [14]: Yield: 80%; m.p.: 238–241 C (dec.); [α]2D0 = +228 (c: 0.54, DCM). H-NMR
(CDCl3) : 7.29–8.23 (several broad m, ~26H), 7.35 (m, 2H); 7.05 (br.ddd, J = 8.5, 6.9, 1.0 Hz, 2H); 6.90 (d,
J = 8.5 Hz, 2H); 4.76–4.92 (br.m, 2H); 4.48–4.65 (br.m, 4H); 2.73–3.25 (br.m, 2H) ppm. 13C-NMR (CDCl3)
: 143.52 (C); 142.87 (br.C); 136.31 (br.C); 135.95 (C); 133.62 (C); 132.96 (br.C); 132.37 (br.C); 131.05 (CH);
◦
1
δ
δ
130.40 (C); 129.39 (CH); 128.95 (several br.CH); 128.07 (CH); 127.64 (br.CH); 127.35 (CH); 126.97 (CH);
126.88 (CH); 126.78 (CH); 126.70 (CH); 126.59 (CH); 126.48 (CH); 125.48 (br.C); 124.11 (br.C); 62.96
(CH2); 57.55 (br.CH2) ppm. HRMS (ESI) calcd. for C56H40N [M − Br]+: 726.3155, found: 726.3145.
(S)-4,8-Di([1,10-biphenyl]-4-yl)-30,5,50,7-tetrahydrospiro[dibenzo[c,e]azepine-6,40-dinaphtho[2,1-c:10,20-e]azepin]-
6-ium bromide (4c): Yield: 75%; m.p.: 236–241 ◦C; [α]D20 = +211 (c: 0.62, DCM). 1H-NMR (500 MHz,
DMSO-d6, 378 K) δ: 7.98 (br.m, 2H); 7.93 (br.d, J = 8.3 Hz, 2H); 7.88 (s, 2H); 7.85–7.90 (m, 2H); 7.62–7.66
(m, 2H); 7.58 (br.m, 2H); 7.46 (ddd, J = 8.0, 6.8, 1.0 Hz, 2H); 7.23–7.45 (br.m, ~14H); 7.21 (ddd, J = 8.2,
6.8, 1.1 Hz, 2H); 7.06 (d, J = 8.5 Hz, 2H); 7.04 (br.m, 4H); 4.49 (d, J = 13.3 Hz, 2H); 4.48 (br.m, 2H); 4.35
(d, J = 13.3 Hz, 2H); 2.65 (br.m, 2H) ppm. 13C-NMR (125.8 MHz, DMSO-d6, 378 K)
δ: 142.60 (C); 141.81
(C); 139.77 (C); 138.81 (C); 137.08 (C); 135.38 (C); 133.17 (C); 130.31 (CH); 129.75 (br.CH); 129.64 (C);
129.43 (CH); 128.64 (CH); 128.37 (CH); 128.03 (CH); 127.70 (CH); 126.83 (CH); 126.70 (CH); 126.44 (CH);
126.24 (CH); 125.97 (2CH); 125.87 (C); 125.69 (CH); 124.33 (C); 62.16 (CH2); 56.78 (CH2) ppm. HRMS
(ESI) calcd for C60H44N [M − Br]+: 778.3468, found: 778.3451.
5A–C (General Procedure C) A round-bottomed flask (10 mL) was charged with racemic dibromide
7
(0.2 mmol) and secondary amine (0.8 mmol for 5A and 0.4 mmol for 5B and 5C, respectively) in
MeCN (4 mL). To this was added K2CO3 (110 mg, 0.8 mmol) and the reaction was stirred for 22–24
h at 80 ◦C. Volatiles were removed under vaccum and the residue was suspended in water (2 mL).
The precipitate was separated, washed with water (2 mL), Et2O (2
yellow solid which was found to be pure by 1H-NMR.
×
2 mL) and air-dried to give a pale
4,4-Dibutyl-2,6-diiodo-4,5-dihydro-3H-dinaphtho[2,1-c:10,20-e]azepin-4-ium bromide (5A): Yield: 86%; m.p.:
◦
220–225 C. 1H-NMR (CDCl3)
δ: 8.70 (s, 2H); 7.89 (d, J = 8.2 Hz, 2H); 7.59 (ddd, J = 8.0, 6.9, 1.0 Hz, 2H);
7.32 (ddd, J = 8.2, 6.9, 1.2 Hz, 2H); 7.09 (d, J = 8.7 Hz, 2H); 5.12 (d, J = 13.9 Hz, 2H); 3.97 (d, J = 13.7 Hz,
2H); 3.52 (m, 4H); 2.18 (m, 2H); 1.83 (m. 2H); 1.51 (m, 4H); 1.02 (t, J = 7.4 Hz, 6H) ppm. 13C-NMR
(CDCl3) δ: 141.36 (CH); 137.89 (C); 135.31 (C); 130.88 (C); 128.87 (CH); 128.16 (CH); 127.71 (C); 127.47
(CH); 127.44 (CH); 97.56 (C); 66.01 (CH2); 59.60 (CH2); 25.44 (CH2); 19.97 (CH2); 13.69 (CH3) ppm.
HRMS (ESI) m/z: Calcd. for C30H32I2N [M − Br]+: 660.0619, found: 660.0610.
2,6-Diiodo-3,5-dihydrospiro[dinaphtho[2,1-c:10,20-e]azepine-4,10-piperidin]-4-ium bromide (5B): Yield: 85%;
1
m.p.: ~290 ◦C (dec.). H-NMR (CDCl3)
δ: 8.71 (s, 2H); 7.89 (d, J = 8.3 Hz, 2H); 7.60 (ddd, J = 8.0, 6.9,
1.1 Hz, 2H); 7.33 (ddd, J = 8.2, 6.9, 1.2 Hz, 2H); 7.10 (dm, J = 8.6 Hz, 2H); 5.42 (d, J = 13.9 Hz); 4.11 (m,
2H); 3.88 (m, 2H); 3.76 (d, J = 13.8 Hz, 2H); 2.38 (m, 2H); 2.10 (m, 2H); 2.02 (m, 2H) ppm. 13C-NMR
(CDCl3) δ: 141.42 (CH); 137.97 (C); 135.27 (C); 130.69 (C); 128.84 (CH); 128.14 (CH); 128.06 (C); 127.40
(CH); 96.99 (C); 65.34 (CH2); 59.23 (CH2); 21.80 (CH2); 20.42 (CH2) ppm. HRMS (ESI) m/z: Calcd. for
C27H24I2N [M − Br]+: 615.9993, found: 616.0016.

Molecules 2018, 23, 750
12 of 18
2,6-Diiodo-3,5-◦dihydrospiro[dinaphtho[2,1-c:10,20-e]azepine-4,10-pyrrolidin]-4-ium bromide (5C): Yield: 94%;
m.p.: 234–238 C. 1H-NMR (CDCl3)
δ: 8.71 (s, 2H); 7.90 (ddd, J = 8.0, 6.8, 1.0 Hz, 2H); 7.35 (ddd, J = 8.2,
6.9, 1.3 Hz, 2H); 7.14 (br.d, J = 8.5 Hz, 2H); 5.25 (d, J = 13.8 Hz, 2H); 4.24 (m, 2H); 4.09 (m, 2H); 3.92
(d, J = 13.7 Hz, 2H); 2.62 (m, 2H); 2.51 (m, 2H) ppm. 13C-NMR (CDCl3)
: 141.46 (CH); 137.65 (C);
135.34 (C); 130.75 (C); 128.80 (CH); 128.66 (C); 128.17 (CH); 127.49 (CH); 127.39 (CH); 96.56 (C); 65.03
δ
(CH2); 62.55 (CH2); 22.16 (CH2) ppm. HRMS (ESI) m/z: Calcd. for C26H22I2N [M
found 601.9861.
−
Br]+: 601.9836,
(S)-2,20-Bis(bromomethyl)-3,30-diiodo-1,10-binaphthalene ( ) [21]: (S)-2,20-Bis(hydroxymethyl)-3,30-diiodo-
7
1,10-binaphthalene (2.971 g, 5.247 mmol) was suspended in HBr (30% in HOAc, 50 mL) and heated to
90 ◦C for 1.5 h. The cooled reaction mixture was poured into water (500 mL) and sufficient DCM was
added to dissolve the precipitate (usually 350–400 mL). The aqueous layer was extracted with DCM
(2
dried (MgSO4). Evaporation afforded crude
(96%, 99% purity by NMR). The material was pure enough for the next step.
×
50 mL) and the combined organic phases washed with water, sat. NaHCO3, and sat. NaCl and
7
as a pale yellow crystalline precipitate; yield: 3.531 g
(S)-2,6-Diiodo-4,5-dihydro-3H-dinaphtho[2,1-c:10,20-e]azepine (
): In a pressure tube with stirring bar
dibromide (1 mmol, 692 mg) was suspended in aqueous NH3 (25%, 15 mL) and acetonitrile (25 mL)
8
7
and the mixture was heated to 60 ◦C (oil bath) with stirring for 24 h. The pressure tube was opened
at r.t. and the slurry was transferred to a 250 mL flask and ammonia and in part acetonitrile was
evaporated. To the residue was added KOH (50 mL, 5% in water) and DCM (50 mL) to obtain a clear
2-phase system. The alkaline phase was extracted with DCM (2
phase was washed neutral, dried (K2CO3) and evaporated to yield 495–520 mg (86–90%) of crude
(95% purity by NMR) which was pure enough for subsequent reactions. Further purification by
chromatography (EtOAc/heptane, 50:50) yielded a crystalline product, m.p.: 239–241 ◦C; [α]D20 = +231
(c: 1.0, EtOH). 1H-NMR (CDCl3)
: 8.58 (s, 2H); 7.81 (d, J = 8.3 Hz, 2H); 7.45 (m, 2H); 7.26 (m, 4H); 4.35
(d, J = 12.8 Hz, 2H); 3.34 (d, J = 12.8 Hz, 2H); ~2.10 (br.s, 1H) ppm. 13C-NMR (CDCl3)
: 139.78 (CH);
×
20 mL) and the combined organic
8
δ
δ
136.05 (C); 135.63 (C); 134.17 (C); 130.80 (C); 127.38 (CH); 127.14 (CH); 126.61 (CH); 126.42 (CH); 97.74
(C); 52.57 (CH2) ppm. HRMS (ESI) calcd. for C22H16I2N [M + H]+: 547.9372, found: 547.9367.
0
0
0
0
0
(11bS,11b S)-4,4 -(((S)-3,3 -Diiodo-[1,1 -binaphthalene]-2,2 -diyl)bis(methylene))bis(2,6-diiodo-4,5-dihydro-3H-
0
0
◦
1
dinaphtho[2,1-c:1 ,2 -e]azepine) (8X) (by-product). m.p.: 233–236 C (dec.). H-NMR (CDCl3, 600 MHz) δ:
8.54 (s, 2H); 8.43 (s, 4H); 7.74 (d, J = 8.2 Hz, 4H); 7.49 (m, 2H); 7.37–7.42 (m, 6H); 7.16 (m, 4H); 7.01–7.10
(m, 8H); 4.37 (d, J = 13.7 Hz, 2H); 3.79 (d, J = 13.6 Hz) ppm; In addition a broad band was observed
(2.3–3.5 ppm); integration corresponding to ~4H. 13C-NMR (CDCl3, 151 MHz)
δ: 139.81 (C); 139.00
(CH); 138.92 (CH); 136.22 (C); 134.06 (C); 134.02 (C); 133.88 (C); 130.73 (C); 129.16 (CH); 127.30 (CH);
127.03 (CH); 126.28 (CH); 126.10 (2CH); 125.76 (CH); 125.36 (CH); 99.50 (C); 98.74 (C); 62.68 (CH2) ppm
(1CH2 not observed). HRMS (ESI) calcd. for C66H43I6N2 [M + H]+: 1624.7694, found: 1624.7684.
Suzuki-Miyaura coupling of (S)-
equipped with magnetic stirring bar and glass stopper, was charged with a solution of diiodoazepine
(S)- (274 mg, 0.50 mmol) in toluene (10 mL) and a Na2CO3-solution (2 M in H2O, 5.0 mL). Then
8 yielding (S)-9a–9c (General Procedure D): A Schlenk tube,
8
arylboronic acid (2.0 mmol, 4 eq) in a minimum amount of EtOH (~2 mL) was added and the mixture
was degassed. After the addition of Pd(PPh3)4 (115 mg, 20 mol %), the reaction was left stirring at
◦
80 C for 48 h. The reaction was monitored by TLC (EtOAc/heptane, 30/70). After cooling to r.t.,
DCM (50 mL) and H2O (30 mL) were added and the phases were separated. The aqueous phase was
extracted with DCM (3
×
20 mL). The combined organic phases were washed with KOH solution (10%,
20 mL) and sat. NaCl solution and dried (K2CO3). After evaporation of solvents the crude material
was purified by MPLC using a solvent gradient (EtOAc + 5% triethylamine(0→30%)/heptane).
(S)-2,6-Diphenyl-4,5-dihydro-3H-dinaphtho[2,1-c:1 ,2 -e]azepine (9a) [33]: Yield: 77%; glassy material; [α]D20
0
0
1
= +294 (c: 0.56, DCM). H-NMR (CDCl3)
δ
: 7.95 (s, 2H); 7.94 (br.d, J = 8.2 Hz, 2H); 7.60 (m, 4H);
7.38–7.50 (m, 10H); 7.27 (ddd, J = 8.5, 6.7, 1.2 Hz, 2H); 4.00 (d, J = 12.5 Hz, 2H); 3.36 (d, J = 12.5 Hz, 2H)

Molecules 2018, 23, 750
13 of 18
ppm. 13C-NMR (CDCl3)
δ
: 141.35 (C); 139.75 (C); 136.00 (C); 133.37 (C); 132.44 (C); 130.80(C); 129.65
(CH); 129.60 (CH); 128.26 (CH); 128.19 (CH); 127.53 (CH); 127.16 (CH); 125.76 (CH); 125.69 (CH); 44.58
(CH2) ppm. HRMS (ESI) calcd for C34H26N [M + H]+: 448.2065, found: 448.2054.
0
0
(S)-2,6-Di(naphthalen-2-yl)-4,5-dihydro-3H-dinaphtho[2,1-c:1 ,2 -e]azepine (9b): Yield: 68%; glassy material;
[α]2D0 = +221 (c: 0.48, DCM). 1H-NMR (CDCl3)
: 8.08 (br.d, J = 1.2 Hz, 2H); 8.06 (s, 2H); 7.89–8.00 (m,
8H); 7.75 (dd, J = 8.3, 1.5 Hz, 2H); 7.48–7.56 (m, 8H); 7.31 (m, 2H); 4.08 (d, J = 12.6 Hz, 2H); 3.44 (d,
J = 12.6 Hz, 2H) ppm. 13C-NMR (CDCl3)
: 139.70 (C); 138.93 (C); 136.10 (C); 133.53 (C); 133.35 (C);
δ
δ
132.53 (C); 132.50 (C); 130.93 (C); 129.92 (CH); 128.32 (2CH); 128.15 (CH); 128.09 (CH); 127.72 (CH);
127.62 (CH); 127.57 (CH); 126.32 (CH); 126.01 (CH); 125.83 (CH); 125.79 (CH); 44.74 (CH2) ppm. HRMS
(ESI) calcd. for C42H30N [M + H]+: 548.2378, found: 548.2383.
(S)-2,6-D◦i([1,10-biphenyl]-4-yl)-4,5-dihydro-3H-dinaphtho[2,1-c:10,20-e]azepine (9c): Yield: 68%; m.p.:
185–190 C; [α]2D0 = +274 (c: 0.49, DCM). H-NMR (CDCl3)
δ: 8.01 (s, 2H); 7.97 (br.d, J = 8.2 Hz,
1
2H); 7.66–7.73 (m, 12H); 7.45–7.52 (m, 8H); 7.38 (m, 2H); 7.29 (ddd, J = 8.6, 6.8, 1.4 Hz, 2H); 4.10 (d,
J = 12.5 Hz, 2H); 3.41 (d, J = 12.5 Hz, 2H) ppm. 13C-NMR (CDCl3)
δ: 140.77 (C); 140.30 (C); 140.03 (C);
139.32 (C); 136.06 (C); 133.33 (C); 132.46 (C); 130.82 (C); 130.10 (CH); 129.65 (CH); 128.83 (CH); 128.29
(CH); 127.54 (CH); 127.35 (CH); 127.12 (CH); 126.94 (CH); 125.81 (CH); 125.76 (CH); 44.65 (CH2) ppm.
HRMS (ESI) calcd. for C46H34N [M + H]+: 600.2686, found: 600.2704.
3,30-Bis(trimethylsilyl)-[1,10-biphenyl]-2,20-dicarboxylic acid: A solution of 2,2,6,6-teramethylpiperidine
◦
(1.730 g, 12 mmol, 2.08 mL) in THF (20 mL) was degassed and cooled to 0 C. To this was added
n-BuLi (4.80 mL of a 2.5 molar solution, 12 mmol) and stirring was continued for 20 min. The reaction
was cooled to
−
78 ◦C and Me3SiCl (2.53 mL, 20 mmol) was added followed by dropwise addition of
diphenic acid (484 mg, 2 mmol) in degassed THF (10 mL) during 30 min. The mixture was allowed to
reach r.t. overnight. For work-up HCl (4 M, 20 mL) was carefully added with stirring followed by Et2O
(40 mL). The aqueous phase was extracted with Et2O (20 mL) and the combined organic phases stirred
with NaOH (1 molar, 40 mL) for 15 min. The organic phases was washed another time with NaOH and
the alkaline extracts washed with ether (20 mL) and acidified (HCl, 6 M). The mixture was extracted
with Et2O (2
×
100 mL) and the combined organic phase was washed with brine and dried (MgSO4).
Evaporation of solvent left 704 mg (90%) of 3,30-bis(trimethylsilyl)-[1,10-biphenyl]-2,20-dicarboxylic
◦
acid as an off-white powder which was pure enough for the next step (99% by NMR). M.p.: 199–202 C.
1H-NMR (CDCl3)
δ: 7.62 (dd, J = 7.5, 1.2 Hz, 2H); 7.39 (t, J = 7.5 Hz, 2H); 7.20 (dd, J = 7.6, 1.2 Hz, 2H);
0.32 (s, 18H) ppm. 13C-NMR (CDCl3)
δ
: 173.71 (C); 138.73 (C); 138.08 (C); 137.47 (C); 134.42 (CH);
130.15 (CH); 129.22 (CH); 0.24 (CH3) ppm. HRMS (ESI) calcd. for C20H25O4Si2 [M
found 385.1298.
−
H]−: 385.1297,
(3,300-Bis(trimethylsilyl)-[1,10-biphenyl]-2,20-diyl)dimethanol: To a degassed solution of 3,30-bis(trimethylsilyl)-
0
[1,1 -biphenyl]-2,2 -dicarboxylic acid (3.67 g, 9.50 mmol) in THF (180 mL) was added BH3
·
THF complex
(38 mL of a 1 M solution in THF, 38 mmol, 4 eq.) by syringe and the reaction was refluxed under
Ar for 20–24 h (TLC control). Diluted HCl (2 M) was carefully added at 0 ◦C to decompose excess
of BH3. After removing bulk of THF the residue was partioned between HCl (2 M, 200 mL) and
DCM (400 mL). The aqueous phase was extracted with more DCM (100 mL and 50 mL) and the
combined organic phase was washed with water and brine and dried (MgSO4). Evaporation of
1
solvents and drying under vacuum overnight left 3.299 g (95% purity by H-NMR, 92% yield) of
(3,30-bis(trimethylsilyl)-[1,10-biphenyl]-2,20-diyl)dimethanol which was pure enough for the next step.
M.p.: 171–175 ◦C. 1H-NMR (CDCl3)
δ: 7.59 (dd, J = 7.5, 1.5 Hz, 2H); 7.32 (t, J = 7.5 Hz, 2H); 7.17 (dd,
J = 7.5, 1.4 Hz, 2H); 4.54 (d, J = 11.5 Hz, 2H); 4.50 (d, J = 11.5 Hz, 2H); 2.56 (br.s, 2H); 0.40 (s, 18H) ppm.
13C-NMR (CDCl3)
δ: 143.43 (C); 141.77 (C); 141.00 (C); 134.44 (CH); 130.94 (CH); 126.83 (CH); 61.83
(CH2); 0.83 (CH3) ppm. HRMS (ESI) calcd. for C20H31O2Si2 [M + Na]+: 381.1682, found: 381.1677.
(3,30-Diiodo-[1,10-biphenyl]-2,20-diyl)dimethanol: A solution of ICl (4.14 g, 25.5 mmol, 3 eq.) in DCM
(100 mL) was dropwise added to (3,30-bis(trimethylsilyl)-[1,10-biphenyl]-2,20-diyl)dimethanol (3.21 g,

Molecules 2018, 23, 750
14 of 18
◦
40 C and the reaction was stirred
8.5 mmol, 95% purity from the previous step) in DCM (140 mL) at
−
at the same temperature for 2 h. A solution of NaHSO3 (100 mL, 10%) was added with vigorous
stirring and after formation of a semifrozen slury the mixture was warmed up to r.t. The crystalline
product was separated, washed with some water and Et2O and dried under vacuum to give 3.435 g of
product. The organic phase was separated, washed with water and dried (MgSO4) and evaporated.
The residue was treated with DCM/heptane (1:1, 10 mL)0to leave a white precipitate which was pure
0
0
product as well, giving a total yield of 3.763 g (95%) of (3,3 -diiodo-[1,1 -biphenyl]-2,2 -diyl)dimethanol.
M.p.: 230–233 ◦C. 1H-NMR (CDCl3)
δ: 7.94 (dd, J = 7.9, 1.3 Hz, 2H); 7.11 (dd, J = 7.6, 1.3 Hz, 2H); 7.02
(t, J = 7.7 Hz, 2H); 4.52 (d, J = 12.2 Hz, 2H); 4.36 (d, J = 12.3 Hz, 2H); 3.32 (br.s, 2H) ppm. 13C-NMR
(CDCl3) δ: 141.84 (C); 140.62 (C); 139.88 (CH); 129.87 (CH); 129.29 (CH); 102.04 (C); 65.75 (CH2) ppm.
HRMS (ESI) calcd. for C14H12I2NaO2 [M + Na]+: 488.8824, found 488.8821.
2,20-Bis(bromomethyl)-3,30-diiodo-1,10-biphenyl (13): To a mixture of HBr (100 mL, 30% in HOAc) and
HOAc (100 mL) was added (3,30-diiodo-[1,10-biphenyl]-2,20-diyl)dimethanol (3.593 g, 7.71 mmol)
and the mixture was refluxed for 2 h. Upon cooling the first crop of product crystallized which
was separated and dried under vacuum (3.776 g, 83%). To the clear filtrate was added ice water
(300 mL) and DCM (200 mL). The aqueous phase was separated and extracted with DCM (2
×
50 mL).
The combined organic phase was washed with water, sat. NaHCO3 solution and brine and dried
(MgSO4). Evaporation gave a slightly less pure second crop of product (>90% NMR, 412 mg, 8%); total
yield of 13: 91%; m.p.: 173–175 ◦C. 1H-NMR (CDCl3)
δ
: 7.96 (dd, J = 8.0, 1.3 Hz, 2H); 7.26 (dd, J = 7.6,
1.2 Hz, 2H); 7.06 (t, J = 7.8 Hz, 2H); 4.43 (d, J = 10.2 Hz, 2H); 4.29 (d, J = 10.2 Hz, 2H) ppm. 13C-NMR
(CDCl3) δ: 141.10 (C); 140.62 (CH); 137.51 (C); 130.08 (CH); 129.69 (CH); 102.02 (C); 37.64 (CH2) ppm.
HRMS (EI) calcd. for C14H1079Br81BrI2: 591.7218, found: 591.7278.
4,8-Diiodo-6,7-dihydro-5H-dibenzo[c,e]azepine (14): A similar procedure as in the synthesis of
8 was
applied with following modifications: The reaction was conducted at 50 ◦C for 48 h and the crude
product was purified by MPLC in a solvent gradient (MeOH(0
amounts of N-spiro compound 14X.
→
10)/DCM) to yield 14 and minor
◦
14: Yield: 73–77%; m.p.: 164–167 C. 1H-NMR (CDCl3)
δ
: 7.91 (dd, J = 7.9, 1.2 Hz, 2H); 7.39 (dd, J = 7.6,
1.2 Hz, 2H); 7.09 (t, J = 7.8 Hz, 2H); 3.79 (br.m, 4H) ppm. 13C-NMR (CDCl3)
δ
: 142.33 (C); 139.51 (CH);
138.94 (C); 129.21 (CH); 127.93 (CH); 100.56 (C); 53.20 (CH2) ppm. HRMS (ESI) calcd. for C14H12I2N
[M + H]+: 447.9054, found: 447.9050.
◦
14X: Yield: 8–13%; m.p.: 295–298 C. 1H-NMR (CDCl3)
δ: 8.13 (dd, J = 8.0, 1.1 Hz, 4H); 7.70 (dd, J = 7.8,
1.1Hz, 4H); 7.47 (t, J = 7.9 Hz, 4H); 4.88 (d, J = 13.7 Hz, 4H); 4.59 (d, J = 13.7 Hz, 4H) ppm. 13C-NMR
(CDCl3) δ: 142.75 (C); 141.31 (CH); 133.56 (CH); 130.27 (CH); 128.90 (C); 103.79 (C); 67.36 (CH2) ppm.
HRMS (ESI) calcd for C28H20I4N [M − Br]+: 877.7769, found: 877.7763.
Suzuki-Miyaura coupling of 14 yielding 15a–15c: General Procedure D was applied with exception
of condition for the MPLC separations; a gradient EtOAc(20→50%)/heptane was used.
1
4,8-Diphenyl-6,7-dihydro-5H-dibenzo[c,e]azepine (15a): Yield: 78%; colorless foam. H-NMR (CDCl3)
δ
:
7.35–7.55 (m, 16H); 3.65 (br.m, 4H) ppm. 13C-NMR (CDCl3)
δ: 142.55 (C); 142.02 (C); 141.28 (C); 134.24
(C); 129.74 (CH); 129.46 (CH); 128.17 (CH); 127.38 (CH); 127.18 (CH); 127.13 (CH); 45.20 (CH2) ppm.
HRMS (ESI) calcd. for C26H22N [M + H]+: 348.1752, found 348.1740.
1
4,8-Di(naphthalen-2-yl)-6,7-dihydro-5H-dibenzo[c,e]azepine (15b): Yield: 76%; colorless foam. H-NMR
(CDCl3)
δ
: 7.98 (br.s, 2H); 7.87–7.93 (m, 6H); 7.68 (dd, J = 8.1, 1.5 Hz, 2H); 7.59 (dd, J = 6.4, 2.6 Hz, 2H);
: 142.61 (C); 141.94 (C); 138.83 (C); 134.45
7.49–7.55 (m, 8H); 3.73 (br.m, 4H) ppm. 13C-NMR (CDCl3)
δ
(C); 133.29 (C); 132.47 (C); 130.02 (CH); 128.14 (CH); 128.10 (CH); 128.00 (CH); 127.68 (CH); 127.65 (CH);
127.52 (CH); 127.27 (CH); 126.27 (CH); 125.97 (CH); 45.32 (CH2) ppm. HRMS (ESI) calcd. for C34H26N
[M + H]+: 448.2065, found 448.2057.

Molecules 2018, 23, 750
15 of 18
4,8-Di([1,10-biphenyl]-4-yl)-6,7-dihydro-5H-dibenzo[c,e]azepine (15c): After extractive work-up large
amount of product crystallized upon addition of diethylether of a concentrated solution in DCM; from
the mother liquor more product was obtained by chromatography; total yield: 85%; m.p.: 250–255 ◦C.
1H-NMR (CDCl3)
2H); 7.44–7.49 (m, 6H); 7.34–7.40 (m, 2H); 3.75 (br.m, 4H) ppm. 13C-NMR (CDCl3)
δ
: 7.63–7.70 (m, 8H); 7.59–7.63 (m, 4H); 7.57 (dd, J = 7.6, 1.5 Hz, 2H); 7.51 (t, J = 7.4 Hz,
δ
: 142.62 (C); 141.63
(C); 140.79 (C); 140.25 (C); 140.04 (C); 134.28 (C); 129.92 (CH); 129.75 (CH); 128.81 (CH); 127.46 (CH);
127.35 (CH); 127.29 (CH); 127.10 (CH); 126.93 (CH); 45.29 (CH2) ppm. HRMS (ESI) calcd. for C38H30N
[M + H]+: 500.2378, found: 500.2368.
Synthesis of diiodo bisazepinium compounds 16, 18, and 19 (Typical procedure): To diiodoazepine
(S)-
8
or 14 (0.5 mmol) and dibromide (S)-10 or 11 (0.5 mmol), respectively in acetonitrile (5◦mL) was
added dry K2CO3 (414 mg, 3 mmol) and the suspension was degassed and stirred at 80 C under
argon overnight. After cooling to room temperature DCM (50 mL) and water (20 mL) was added.
The aqueous phase was separated and extracted with DCM (3
×
10 mL). The combined organic layers
were evaporated and the crude products purified by MPLC in MeOH (0→10%)/DCM.
(S,S)-2,6-Diiodo-3,30,5,50-tetrahydro-4,40-spirobi[dinaphtho[2,1-c:10,20-e]azepin]-4-ium bromide (16): Yield:
65%; m.p.: 216–219 ◦C (dec.); [α]D20 = +261 (c: 0.46, DCM). 1H-NMR (DMSO-d6)
δ: 9.08 (s, 2H); 8.52
(d, J = 8.5 Hz, 2H); 8.31 (d, J = 8.6 Hz, 2H); 8.18 (d, J = 8.2 Hz, 2H); 8.15 (d, J = 8.3 Hz, 2H); 7.65 (ddd,
J = 6.8, 2.9, 1.0 Hz, 2H); 7.63 (ddd, J = 6.8, 3.0, 1.2 Hz, 2H); 7.36 (m, 4H); 7.13 (br.d, J = 8.7 Hz, 2H); 6.80
(br.d, J = 8.6 Hz, 2H); 4.79 (d, J = 14.8 Hz, 2H); 4.43 (d, J = 14.2 Hz, 2H); 4.35 (d, J = 14.2 Hz, 2H); 4.33 (d,
J = 14.8 Hz, 2H) ppm. 13C-NMR (DMSO-d6)
δ: 141.06 (CH); 137.28 (C); 135.98 (C); 134.93 (C); 134.08
(C); 131.93 (CH); 130.99 (C); 130.93 (C); 128.86 (CH);128.44 (CH); 128.30 (CH); 127.76 (CH); 127.35 (C);
127.33 (CH); 127.29 (CH); 127.17 (CH); 126.80 (CH); 126.68 (CH); 125.69 (C); 97.09 (C); 64.94 (CH2);
62.29 (CH2) ppm. HRMS (ESI) calcd. for C44H30I2N [M − Br]+: 826.0462, found: 826.0480.
(S)-20,60-Diiodo-30,5,50,7-tetrahydrospiro[dibenzo[c,e]azepine-6,40-dinaphtho[2,1-c:10,20-e]azepin]-6-ium
bromide (18): Yield: 69%; m.p.: 255–259 ◦C (dec.); [α]D20 = +74 (c: 0.81, DCM) 1H-NMR (CDCl3)
δ: 8.69
(s, 2H); 8.04 (d, J = 8.0 Hz, 2H); 7.92 (d, J = 8.2 Hz, 2H); 7.68–7.73 (m, 4H); 7.62 (t, J = 7.5 Hz, 2H); 7.57
(m, 2H); 7.36 (t, J = 8.0 Hz, 2H); 7.24 (d, J = 8.7 Hz, 2H); 5.12 (d, J = 13.5 Hz, 2H); 5.02 (d, J = 13.5 Hz,
2H); 4.88 (d, J = 12.6 Hz, 2H); 4.38 (d, J = 12.6 Hz, 2H) ppm. 13C-NMR (CDCl3)
δ: 141.33 (CH); 141.08
(C); 138.55 (C); 135.73 (C); 132.02 (CH); 131.61 (C); 131.55 (CH); 129.50 (CH); 128.69 (CH); 128.66 (CH);
128.01 (CH); 127.69 (CH); 127.60 (CH); 127.60 (C); 127.15 (C); 96.80 (C); 66.78 (CH2); 63.26 (CH2) ppm.
HRMS (ESI) calcd. for C36H26I2N [M − Br]+: 726.0149, found: 726.0152.
0
0
0
0
0
(S)-4,8-Diiodo-3 ,5,5 ,7-tetrahydrospiro[dibenzo[c,e]azepine-6,4 -dinaphtho[2,1-c:1 ,2 -e]azepin]-6-ium bromide
(
19): Yield: 93%; m.p.: 279–281 C (dec.); [α]2D0 = +86 (c: 0.62, DCM). H-NMR (CDCl3)
δ: 8.27 (d,
◦
1
J = 8.4 Hz, 2H); 8.15 (d, J = 8.4 Hz, 2H); 8.06 (dm, J = 8.4 Hz, 2H); 8.01 (dd, J = 8.1, 1.2 Hz, 2H); 7.63
(ddd, J = 8.1, 6.8, 1.1 Hz, 2H); 7.61 (dd, J = 7.7, 1.2 Hz, 2H); 7.54 (dm, J = 8.6 Hz, 2H); 7.41 (ddd, J = 8.5,
6.8, 1.3 Hz, 2H); 7.36 (t, J = 7.9 Hz, 2H); 5.26 (d, J = 12.7 Hz, 2H); 5.16 (d, J = 13.8 Hz, 2H); 4.70 (d,
J = 13.6 Hz, 2H); 4.46 (d, J = 12.7 Hz, 2H) ppm. 13C-NMR (CDCl3)
δ: 143.36 (C); 140.73 (CH); 136.92
(C); 134.51 (C); 132.78 (CH); 131.12 (C); 130.39 (CH); 130.24 (CH); 130.01 (C); 128.85 (CH); 127.78 (CH);
127.68 (CH); 127.53 (CH); 127.09 (CH); 126.94 (C); 102.69 (C); 66.43 (CH2); 64.32 (CH2) ppm. HRMS
(ESI) calcd. for C36H26I2N [M − Br]+: 726.0149, found: 726.0138.
(R)-4-(((S)-20-Benzyl-[1,10-binaphthalen]-2-yl)methyl)-2,6-diphenyl-4,5-dihydro-3H-dinaphtho[2,1-c:10,20-e]
1
azepine (17a): Yield: 20–40%. H-NMR (CDCl3)
δ
: 8.03 (d, J = 8.0 Hz, 1H); 7.96 (d, J = 8.0 Hz, 2H); 7.89
(d, J = 8.5 Hz, 1H); 7.80 (d, J = 8.3 Hz, 1H); 7.77 (s, 2H); 5.58 (s, 2H); 7.54 (m, 3H); 7.50 (d, J = 8.7 Hz,
2H); 7.33 (m, 3H); 7.23 (m, 2H); 6.97–7.18 (m, 10H); 7.95 (d, J = 8.5 Hz, 1H); 6.86 (d, J = 8.7 Hz, 1H);
6.81 (t, J = 7.3 Hz, 1H); 6.73 (d, J = 8.5 Hz, 1H); 6.63 (t, J = 7.6 Hz, 2H); 6.29 (d, J = 7.6 Hz, 2H); 3.77 (d,
J = 12.8 Hz, 2H); 3.16 (d, J = 16.0 Hz, 1H); 2.99 (d, J = 14.9 Hz, 1H); 2.84–2.94 (br.m, 4H) ppm. 13C-NMR
(CDCl3)
δ: 140.90 (C); 140.45 (C); 139.65 (C); 136.22 (C); 136.04 (C); 135.00 (C); 134.12 (C); 133.85 (C);
133.22 (C); 132.52 (C); 132.43 (C); 132.42 (C); 132.32 (C); 132.06 (C); 130.71 (C); 129.70 (CH); 129.10 (CH);

Molecules 2018, 23, 750
16 of 18
128.55 (CH); 128.29 (CH); 127.99 (CH); 127.91 (CH); 127.84 (CH); 127.79 (CH); 127.59 (CH); 127.53 (CH);
127.15 (CH); 126.73 (CH); 126.26 (CH); 126.21 (CH); 125.79 (CH); 125.76 (CH); 125.74 (CH); 125.65 (CH);
125.61 (CH); 125.57 (CH); 125.37 (CH); 125.14 (CH); 57.49 (CH2); 51.72 (CH2); 39.31 (CH2) ppm. HRMS
(ESI) calcd. for C62H46N [M + H]+: 804.3625, found: 804.3640.
(R)-2,6-Di(naphthalen-2-yl)-4-(((S)-20-(naphthalen-2-ylmethyl)-[1,10-binaphthalen]-2-yl)methyl)-4,5-dihydro-
0
0
1
3H-dinaphtho[2,1-c:1 ,2 -e]azepine (17b): Yield: 20–30%. H-NMR (CDCl3) δ: 8.04 (d, J = 8.0 Hz, 1H); 8.01
(d, J = 8.2 Hz, 2H); 7.89 (s, 2H); 7.81 (d, J = 8.6 Hz, 1H); 7.79 (br.d, J = 7.8 Hz, 2H); 7.72 (br.s, 2H); 7.69
(br.d, J = 8.0 Hz, 2H); 7.45–7.61 (m, ~11H); 7.28–7.42 (m, 8H); 7.22 (ddd, J = 8.0, 6.8, 1.1 Hz, 1H); 7.08
(ddd, J = 8.3, 6.8, 1.2 Hz, 1H); ~7.0 (br.m, 1H); 7.00 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H); 6.94 (d, J = 8.6 Hz, 1H);
6.90 (br.d, J = 8.4 Hz, 1H); 6.83 (s, 1H); 6.79 (d, J = 8.4 Hz, 1H); ~6.7 (br.m, 1H); 6.69 (d, J = 8.6 Hz, 1H);
6.36 (dd, J = 8.5, 1.6 Hz, 1H); 3.84 (d, J = 12.9 Hz, 2H); 3.24 (d, J = 15.5 Hz, 1H); ~3.1 (br.m, 2H); 3.01 (d,
J = 15.6 Hz, 1H); 3.00 (d, J = 14.6 Hz, 1H); 2.97 (d, J = 14.8 Hz, 1H) ppm. 13C-NMR (CDCl3)
δ: 140.39
(C); 138.47 (C); 137.39 (C); 136.29 (C); 136.15 (C); 135.07 (C); 134.25 (C); 133.79 (C); 133.31 (C); 133.13 (C);
132.94 (C); 132.54 (C); 132.53 (C); 132.32 (C); 132.31 (C); 131.71 (C); 130.88 (C); 128.87 (CH); 128.42 (CH);
128.39 (CH); 128.11 (CH); 128.07 (CH); 128.01 (CH); 127.77 (CH); 127.71 (CH); 127.68 (CH); 127.62 (CH);
127.60 (CH); 127.52 (CH); 127.45 (CH); 127.37 (CH); 127.27 (CH); 127.24 (CH); 126.46 (CH); 126.21 (CH);
126.10 (CH); 125.88 (CH); 125.82 (CH); 125.80 (CH); 125.77 (CH); 125.60 (CH); 125.56 (CH); 125.43 (CH);
125.00 (CH); 124.93 (CH); 57.67 (CH2); 51.90 (CH2); 39.59 (CH2) ppm (2C, 1CH not observed). HRMS
(ESI) calcd. for C74H52N [M − Br]+: 954.4094, found: 954.4095.
3.3. X-ray Analysis
The X-ray intensity data were measured on Bruker D8 Venture diffractometer (Bruker, Billerica,
MA, USA) equipped with multilayer monochromator, Mo K/a and Cu K/a INCOATEC micro focus
sealed tubes and Kryoflex II or Oxford 800 cooling devices. The structures were solved by direct
methods and refined by full-matrix least-squares techniques. Non-hydrogen atoms were refined with
anisotropic displacement parameters. Hydrogen atoms were inserted at calculated positions and
refined with a riding model. The following software was used: Bruker SAINT software package [34
]
sing a narrow-frame algorithm for frame integration, SADABS [35] for absorption correction, OLEX2
(version 1.2.9, OlexSys Ltd, Durham, UK) [36] for structure solution, refinement, molecular diagrams
and graphical user-interface, Shelxle (Rev 833, University of Goettingen, Goettingen, Germany) [37] for
refinement and graphical user-interface SHELXS-2013 [38] for structure solution, SHELXL-2013 [39
for refinement, Platon (version 270106, Utrecht University, Utrecht, Netherlands) [40] for symmetry
check. Crystal data for structures of 3a 16, and 17b are collected in Table 1. Experimental data and
]
, 8,
CCDC-Codes can be found in the Supplementary Materials.
Table 1. Crystal data for 3a, 8, 16, and 17b.
3a
8
16
17b
M [g/mol]
Space group
a [Å]
945.42
C2/c
32.9747(11)
33.7652(11)
19.2774(7)
90
119.5218(14)
90
18676.7(11)
16
866.80
P21
11.8178(7)
17.2708(10)
14.3841(8)
90
94.2551(19)
90
2927.7(3)
4
1161.18
P212121
8.9851(5)
11.0959(7)
44.154(3)
90
90
90
4402.1(5)
4
1.752
1208.93
P-1
12.3238(10)
13.5521(11)
19.1746(19)
71.502(2)
86.172(4)
84.204(3)
3019.4(5)
2
1.330
0.0295
0.0361
0.0707
b [Å]
c [Å]
◦
α [ ]
◦
β [ ]
◦
γ [ ]
V [Å3]
Z
Dcalc [g/cm3]
Rint
1.345
0.1057
0.0620
0.0529
1.967
0.0567
0.0214
0.0215
0.0496
0.0471
0.0263
0.0318
0.0736
Rsigma
R1 (I > 2σ(I))
wR2 (all data)
0.1394
0.1912

Molecules 2018, 23, 750
17 of 18
Supplementary Materials: The following are available on http://www.mdpi.com/1420-3049/23/4/750/s1,
containing 1H- and 13C-NMR charts, details of crystal structure determinations and preparation of precursor 6.
Acknowledgments: S.T. and A.M. are grateful to the Development and Promotion of Science and Technology Talents
Project (DPST) for the financial support. This work was generously supported by the ASEA-UNINET program.
Author Contributions: Synthesis of products was performed by S. Tharamak, C. Knittl-Frank (both 1Aa
–1Cc),
A. Pengsook (3a ), L. Suchy (2a ), P. Schuller (4a ), A. Manaprasertsak, B. Happl (both optical resolution and
–
c
–
c
–c
precursor syntheses), A. Roller conducted crystal structure analyses, and M. Widhalm conceived and designed the
experiments and wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References and Note
1.
Shirakawa, S.; Maruoka, K. Recent Developments in Asymmetric Phase-Transfer Reactions. Angew. Chem.
Int. Ed. 2013, 52, 4312–4348. [CrossRef] [PubMed]
2.
Shirakawa, S.; Maruoka, K. Chiral Onium Salts (Phase-Transfer Reactions). In Comprehensive Enantioselective
Organocatalysis: Catalysts, Reactions, and Applications, 1st ed.; Dalko, P.I., Ed.; Wiley-VCH: Hoboken, NJ, USA,
2013; Volume 2, pp. 365–379.
3.
4.
Kaneko, S.; Kumatabara, Y.; Shirakawa, S. A new generation of chiral phase-transfer catalysts. Org. Biomol. Chem.
2016, 14, 5367–5376. [CrossRef] [PubMed]
Chu, W.-D.; Zhang, L.-F.; Bao, X.; Zhao, X.-H.; Zeng, C.; Du, J.-Y.; Zhang, G.-B.; Wang, F.-X.; Ma, X.-Y.;
Fan, C.-A. Asymmetric Catalytic 1,6-Conjugate Addition/Aromatization of para-Quinone Methides:
Enantioselective Introduction of Functionalized Diarylmethine Stereogenic Centers. Angew. Chem. Int. Ed.
2013, 52, 9229–9233. [CrossRef] [PubMed]
5.
Wang, X.; Kitamura, M.; Maruoka, K. New, Chiral Phase Transfer Catalysts for Effecting Asymmetric
Conjugate Additions of
[CrossRef] [PubMed]
α-Alkyl-α-cyanoacetates to Acetylenic Esters. J. Am. Chem. Soc. 2007, 129, 1038–1039.
6.
7.
8.
9.
Ooi, T.; Uematsu, Y.; Kameda, M.; Maruoka, K. Conformationally Flexible, Chiral Quaternary Ammonium
Bromides for Asymmetric Phase-Transfer Catalysis. Angew. Chem. Int. Ed. 2002, 41, 1551–1554. [CrossRef]
Kitamura, M.; Shirakawa, S.; Maruoka, K. Powerful Chiral Phase-TransferCatalysts for the Asymmetric Synthesis
of α-Alkyl- and α,α-Dialkyl-α-amino Acids. Angew. Chem. Int. Ed. 2005, 44, 1549–1551. [CrossRef] [PubMed]
Ooi, T.; Kameda, M.; Maruoka, K. Molecular Design of a C2-Symmetric Chiral Phase-Transfer Catalyst for
Practical Asymmetric Synthesis of α-Amino Acids. J. Am. Chem. Soc. 1999, 121, 6519–6520. [CrossRef]
Ooi, T.; Takeuchi, M.; Kameda, M.; Maruoka, K. Practical Catalytic Enantioselective Synthesis of
α
,
α
-Dialkyl-
10. Ooi, T.; Takeuchi, M.; Kato, D.; Uematsu, Y.; Tayama, E.; Sakai, D.; Maruoka, K. Highly Enantioselective
Phase-Transfer-Catalyzed Alkylation of Protected -Amino Acid Amides toward Practical Asymmetric
Synthesis of Vicinal Diamines, -Amino Ketones, and -Amino Alcohols. J. Am. Chem. Soc. 2005, 127,
5073–5083. [CrossRef] [PubMed]
α-amino Acids by Chiral Phase-Transfer Catalysis. J. Am. Chem. Soc. 2000, 122, 5228–5229. [CrossRef]
α
α
α
11. Kitamura, K.; Arimura, Y.; Shirakawa, S.; Maruoka, K. Combinatorial approach for the design of new,
simplified chiral phase-transfer catalysts with high catalytic performance for practical asymmetric synthesis
of α-alkyl-α-amino acids. Tetrahedron Lett. 2008, 49, 2026–2030. [CrossRef]
12. Hua, M.-Q.; Cui, H.-F.; Wang, L.; Nie, J.; Ma, J.-A. Reversal of Enantioselectivity by Tuning the Conformational
Flexibility of Phase-Transfer Catalysts. Angew. Chem. Int. Ed. 2010, 49, 2772–2776. [CrossRef] [PubMed]
13. Shirakawa, S.; Wang, L.; He, R.; Arimitsu, S.; Maruoka, K. A Base-Free Neutral Phase-Transfer Reaction
System. Chem. Asian J. 2014, 9, 1586–1593. [CrossRef] [PubMed]
14. Ooi, T.; Uematsu, Y.; Kameda, M.; Maruoka, K. Asymmetric phase-transfer catalysis of homo- and
heterochiral quaternary ammonium salts: Development and application of conformationally flexible chiral
phase-transfer catalysts. Tetrahedron 2006, 62, 11425–11436. [CrossRef]
15. Ooi, T.; Kameda, M.; Maruoka, K. Design of N-Spiro C2-Symmetric Chiral Quaternary Ammonium Bromides
as Novel Chiral Phase-Transfer Catalysts: Synthesis and Application to Practical Asymmetric Synthesis of
α-Amino Acids. J. Am. Chem. Soc. 2003, 125, 5139–5151. [CrossRef] [PubMed]
16. Ooi, T.; Uematsu, Y.; Maruoka, K. New, Improved Procedure for the Synthesis of Structurally Diverse N-Spiro C2
Symmetric Chiral Quaternary Ammonium Bromides. J. Org. Chem. 2003, 68, 4576–4578. [CrossRef] [PubMed]

Molecules 2018, 23, 750
18 of 18
0
0
17. For synthesis of 1,1 -binaphthalene-2,2 -dicarboxylic acid see (selection): Seki, M.; Yamada, S.; Kuroda, K.;
Imashiro, R.; Shimizu, T. A Practical Synthesis of C2-Symmetric Chiral Binaphthyl Ketone Catalyst. Synthesis
2000, 2000, 1677–1680. [CrossRef]
18. Weber, E.; Csoregh, I.; Stensland, B.; Czugler, M. A Novel Clathrate Design: Selective Inclusion of Uncharged
Molecules via the Binaphthyl Hinge and Appended Coordinating Groups. X-ray Crystal Structures
and Binding Modes of 1,10-Binaphthyl-2,20-Dicarboxylic Acid Host/Hydroxylic Guest Inclusions. J. Am.
Chem. Soc. 1984, 106, 3297–3306. [CrossRef]
19. Hashimoto, T.; Maruoka, K. Design of Axially Chiral Dicarboxylic Acid for Asymmetric Mannich Reaction
of Arylaldehyde N-Boc Imines and Diazo Compounds. J. Am. Chem. Soc. 2007, 129, 10054–10055. [CrossRef]
[PubMed]
20. Shi, G.; Zhang, Y. Carboxylate-Directed C-H Functionalisation. Adv. Synth. Catal. 2014, 356, 1419–1442. [CrossRef]
21. Widhalm, M.; Abraham, M.; Arion, V.B.; Saarsalu, S.; Maeorg, U. A modular approach to a new class of
phosphinohydrazones and their use in asymmetric allylic alkylation reactions. Tetrahedron Asymmetry 2010
,
21, 1971–1982. [CrossRef]
22. Hawkins, J.M.; Lewis, T.A. Asymmetric synthesis of erythro and threo .alpha.-substituted beta-amino esters.
J. Org. Chem. 1994, 59, 649–652.
23. Wenner, W. 6,7-Dihydro-5H-Dibenz[c,e]Azepine Derivatives. J. Org. Chem. 1952, 17, 1451–1455. [CrossRef]
24. Scafato, P.; Cunsolo, G.; Labano, S.; Rosini, C. Asymmetric activation of tropos catalysts in the stereoselective
catalytic conjugate additions of R2Zn to
60, 8801–8806. [CrossRef]
α
,β
-enones: an efficient synthesis of ( )-muscone. Tetrahedron 2004,
−
25. Ikunaka, M.; Maruoka, K.; Okuda, Y.; Ooi, T. A Scalable Synthesis of (R)-3,5-Dihydro-4H-
0
0
dinaphth[2,1-c:1 2 -e]azepine. Org. Proc. Res. Dev. 2003, 7, 644–648. [CrossRef]
0
26. Pisani, L.; Superchi, S. 1,1 -Binaphthylazepine-based ligands for the enantioselective dialkylzinc addition to
aromatic aldehydes. Tetrahedron Asymmetry 2008, 19, 1784–1789. [CrossRef]
27. Kitamura, M.; Shirakawa, S.; Arimura, Y.; Wang, X.; Maruoka, K. Combinatorial Design of Simplified
High-Performance Chiral Phase-Transfer Catalysts for Practical Asymmetric Synthesis of α-Alkyl- and
α,α-Dialkyl-α-Amino Acids. Chem. Asian J. 2008, 3, 1702–1714. [CrossRef] [PubMed]
28. Bulman Page, P.C.; Buckley, B.R.; Blacker, A.J. Iminium Salt Catalysts for Asymmetric Epoxidation: The First
High Enantioselectivities. Org. Lett. 2004, 6, 1543–1546. [CrossRef] [PubMed]
29. Bahrmann, H.; Bergrath, K.; Kleiner, H.-J.; Lappe, P.; Naumann, C.; Peters, D.; Regnat, D. BINAS-synthesis
and use of a new ligand for propylene hydroformylation. J. Organomet. Chem. 1996, 520, 97–100. [CrossRef]
0
0
30. Kleiner, H.-J.; Regnat, D.; Röschert, H. Process for Preparing 2,2 -bis(halogenomethyl)-1,1 -binaphthalene.
Patent EP 0675095 B1, 4 October 1995.
31. Underwood, H.W., Jr.; Kochmann, E.L. Studies in Diphenic Acid Series II. J. Am. Chem. Soc. 1924, 46,
2069–2078. [CrossRef]
32. Schroeter, G.; Muller, H.; Huang, J. Über die Hydrierung des Phenanthrens (II. Mitteil.). Chem. Ber. B 1929
62, 645–648. [CrossRef]
,
33. Akhatou, A.; Rahimi, M.; Chebou, K.; Ghosez, L.; Hanquet, G. Acid promoted enantioselective oxygen-atom
transfer from N-alkyl binaphthyl-derived oxaziridines onto sulfides. Tetrahedron 2007, 63, 6232–6240. [CrossRef]
34. Bruker SAINT, version 8.32BA; Bruker AXS: Billerica, MA, USA, 2012.
35. Sheldrick, G.M. SADABS; University of Göttingen: Göttingen, Germany, 1996.
36. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2. J. Appl. Cryst. 2009
42, 339–341. [CrossRef]
,
37. Huebschle, C.B.; Sheldrick, G.M.; Dittrich, B. ShelXle: A Qt graphical user interface for SHELXL. J. Appl. Cryst.
2011, 44, 1281–1284. [CrossRef] [PubMed]
38. Sheldrick, G.M. SHELXS; University of Göttingen: Göttingen, Germany, 1996.
39. Sheldrick, G.M. SHELXL; University of Göttingen: Göttingen, Germany, 1996.
40. Spek, A.L. Structure validation in chemical crystallography. Acta Cryst. D 2009, 65, 148–155. [CrossRef] [PubMed]
Sample Availability: Not available.
©
2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).